Definitive Contract HHSN266200600012C

The National Institute on Drug Abuse, a component of the Department of Health and Human Services' National Institutes of Health, awarded a firm fixed-price purchase order valued at $25,000 to Kaiser Foundation Hospitals Kaiser Foundation Research Institute Division, operating as Kaiser Permanente. The objective of this contract is to investigate Glucagon-Like Peptide-1 (GLP-1) analogues as a novel pharmacotherapeutic approach for Alcohol Use Disorder (AUD). Work will be performed in Baltimore,...

Sri International, a nonprofit research and development organization headquartered in Menlo Park, California, was awarded a definitive cost-plus-fixed-fee contract by the National Institute on Drug Abuse (NIDA) on September 30, 2004, with an ultimate completion date of June 30, 2010. The contract, valued at approximately $4.2 million, supports investigational new drug toxicology research for therapeutic candidates targeting Alzheimer's disease and other age-related conditions. The work will be...

This contract, awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse, is for the synthesis and distribution of drugs of abuse and related compounds. The prime contractor is the non-profit Research Triangle Institute (RTI) International, which has a broad range of scientific and technical capabilities supporting federal initiatives. The potential value of this Delivery Order contract is $2,285,474.00 with a cost plus fixed fee...

The Department of Justice Drug Enforcement Administration (DEA) awarded a $136,383.00 firm fixed price purchase order to The Mclean Hospital Corporation, a non-profit research hospital affiliated with Harvard Medical School, to conduct a study on the drug discrimination and locomotor activity of 15 designer benzodiazepine substances. This study aims to gather pharmacological, medical, and epidemiological data to support the DEA's efforts to place these substances under regulatory control under...

This is a $7,845,352.00 definitive, cost-no-fee contract awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Virginia Commonwealth University (VCU) for medication discovery research using rat models of relapse. The contract supports NIDA's Addiction Treatment Discovery Program, which aims to identify potential pharmacotherapies to prevent relapse to cocaine and other drug abuse. The work involves developing and utilizing rodent...

This contract awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse (HHS-NIH-NIDA) to Research Triangle Institute - doing business as R T I International is for the synthesis and distribution of drugs of abuse and related compounds from June 9, 2023 to June 8, 2024 under Task Order 75N95023F00001 (TO4) of major program N01DA-22-8944. The contract type is a delivery order with a place of performance in Research Triangle Park, North...

This is a $3,358,776 cost-plus-fixed-fee Delivery Order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO). The award is for a Phase I randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of a medical product. The contract is a task order under NIDA's "Phase I Clinical Trials for Development of Neurotherapeutics" Indefinite...

Research Triangle Institute (RTI) International has been awarded a cost-plus-fixed-fee delivery order against a Blanket Purchase Agreement with the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) for $1,495,510. The delivery order is for the period March 20, 2023 through March 19, 2024 and involves the preparation and distribution of research drug products to support NIDA's mission. No set-aside designation was used for this award. RTI will perform the work at its...

The National Institute on Drug Abuse (NIDA) awarded a firm fixed price purchase order valued at $3,988.67 to Yali Zheng on December 30, 2009, with a completion date of January 31, 2010. This contract supports research investigating the regulation of compartmental-specific cytoskeletal protein phosphorylation in neurons and the role of cyclin-dependent kinase 5 (CDK5) in neuronal development, survival, and neurodegeneration. The work is being performed in Bethesda, Maryland. No set-aside...

The Food and Drug Administration awarded a $2.24 million firm fixed-price definitive contract to the Regents of the University of Michigan on September 12, 2024, to conduct research on stimulant and opioid use disorder trajectories and associated consequences in U.S. adults using a mosaic approach. The contract, which will be performed at the University of Michigan in Ann Arbor, Michigan, is scheduled for completion by September 29, 2028. This research aligns with FDA's public health mission and...